Evidence map›Paper›PMID 41906530›Full record

ArticleJournal of immunology research2026

Attenuated Infectious Bronchitis Virus (IBV) Vaccination Induces Protective Humoral and Cellular Immunity Against SARS-CoV-2 in Mammals.

Ney de Carvalho Almeida, Mauricio Fraga van Tilburg, Bruno Bezerra da Silva, João Xavier da Silva Neto, Luiz Francisco Wemmenson Gonçalves Moura, Natália do Vale Canabrava, Diane Isabelle Magno Cavalcante, Deysi Viviana Tenazoa Wong, Roberto César Pereira Lima, Daniel Pascoalino Pinheiro and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Ney de Carvalho AlmeidaBiotechnology and Molecular Biology Laboratory, State University of Ceará, Campus do Itaperi, Fortaleza, 60714-903, Ceará, Brazil, uece.br.
Mauricio Fraga van TilburgBiotechnology and Molecular Biology Laboratory, State University of Ceará, Campus do Itaperi, Fortaleza, 60714-903, Ceará, Brazil, uece.br.
Bruno Bezerra da SilvaBiotechnology and Molecular Biology Laboratory, State University of Ceará, Campus do Itaperi, Fortaleza, 60714-903, Ceará, Brazil, uece.br.
João Xavier da Silva NetoBiotechnology and Molecular Biology Laboratory, State University of Ceará, Campus do Itaperi, Fortaleza, 60714-903, Ceará, Brazil, uece.br.
Luiz Francisco Wemmenson Gonçalves MouraBiotechnology and Molecular Biology Laboratory, State University of Ceará, Campus do Itaperi, Fortaleza, 60714-903, Ceará, Brazil, uece.br.
Natália do Vale CanabravaBiotechnology and Molecular Biology Laboratory, State University of Ceará, Campus do Itaperi, Fortaleza, 60714-903, Ceará, Brazil, uece.br.ORCID https://orcid.org/0000-0002-4841-8989
Diane Isabelle Magno CavalcanteDepartment of Pathology and Forensic Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil, ufc.br.
Deysi Viviana Tenazoa WongLaboratory of Inflammation and Cancer Pharmacology, Drug Research and Development Center (NPDM), Department of Physiology and Pharmacology, Federal University of Ceará, Fortaleza, Brazil, ufc.br.
Roberto César Pereira LimaLaboratory of Inflammation and Cancer Pharmacology, Drug Research and Development Center (NPDM), Department of Physiology and Pharmacology, Federal University of Ceará, Fortaleza, Brazil, ufc.br.
Daniel Pascoalino PinheiroOswaldo Cruz Foundation in Ceará, Eusebio, Brazil.
Dayane Alves CostaOswaldo Cruz Foundation in Ceará, Eusebio, Brazil.
Danúbio Andrade Bezerra FariasBiotechnology and Molecular Biology Laboratory, State University of Ceará, Campus do Itaperi, Fortaleza, 60714-903, Ceará, Brazil, uece.br.
Pablo Abreu de MoraisFederal Institute of Education, Science and Technology of Ceará, Campus Horizonte, Horizonte, Ceará, Brazil.
Valder Nogueira FreireDepartment of Physics, Federal University of Ceará, Fortaleza, Ceará, Brazil, ufc.br.
Valdir Ferreira de PaulaBiotechnology and Molecular Biology Laboratory, State University of Ceará, Campus do Itaperi, Fortaleza, 60714-903, Ceará, Brazil, uece.br.
Francisco Franciné MaiaDepartment of Natural Sciences, Mathematics and Statistics, Universidade Federal Rural do Semi-Árido, Mossoró, 59625-900, Rio Grande do Norte, Brazil, ufersa.edu.br.
Diego Veras WilkePhysiology and Pharmacology Department, Federal University of Ceara, Fortaleza, Ceará, Brazil, ufc.br.
Gilvan Pessoa FurtadoOswaldo Cruz Foundation in Ceará, Eusebio, Brazil.
Eridan Orlando Pereira Tramontina FloreanBiotechnology and Molecular Biology Laboratory, State University of Ceará, Campus do Itaperi, Fortaleza, 60714-903, Ceará, Brazil, uece.br.
Maria Izabel Florindo GuedesBiotechnology and Molecular Biology Laboratory, State University of Ceará, Campus do Itaperi, Fortaleza, 60714-903, Ceará, Brazil, uece.br.ORCID https://orcid.org/0000-0002-4569-8663

Funding

Conselho Nacional de Desenvolvimento Científico e TecnológicoCoordenação de Aperfeiçoamento de Pessoal de Nível SuperiorFundação Cearense de Apoio ao Desenvolvimento Científico e Tecnológico 09565434/2022
6 · The paper itself

Abstract

Occupational exposure to infectious bronchitis virus (IBV) has been associated with cross-reactivity to other coronaviruses such as SARS-CoV-2. In this study, we investigated the immune response of IBV using reconstituted samples of the commercial H120 Mass-I vaccine (Zoetis) against SARS-CoV-2 infection. Bioinformatics analyses, serological assays, and neutralization tests were conducted to evaluate the neutralizing capacity of anti-IBV antibodies against SARS-CoV-2 in serum samples from poultry farm workers exposed to the IBV-H120 vaccine. Mouse immunization assays and flow cytometry analysis were conducted to characterize the immune response triggered by IBV-H120. Finally, a histological analysis of the lungs of Syrian hamsters vaccinated with IBV and challenged with SARS-CoV-2 (Wuhan and Delta strains) was conducted to evaluate the protective potential of the vaccine. Neutralizing antibodies against IBV-H120 were detected in the serum of poultry farm workers, indicating cross-reactivity with SARS-CoV-2. The immune response in mice immunized with IBV-H120 demonstrated that only the intranasal and oral routes were effective against SARS-CoV-2. An increase in the percentage of CD19

Indexed as

COVID-19COVID-19 VaccinesInfectious bronchitis virusSARS-CoV-2Viral VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralCricetinaeCross ReactionsFemaleHumansImmunity, CellularImmunity, HumoralLungMesocricetusAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesVaccines, AttenuatedViral Vaccinesalternative vaccinecross-protectioninfectious bronchitis virusrespiratory infectionvaccine protection

Identifiers

PMID41906530
PMCPMC13140183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.